Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer

NCT00679783 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

99

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Carcinoma
Breast Cancer

Interventions

DRUG: AZD2281

Sponsor

AstraZeneca

Collaborators

[object Object]